PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Probiotic”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 343 records · Page 19Linked to original sources

Effect of milk base and starter culture on acidification, texture, and probiotic cell counts in fermented milk processing.

In the present work, the compared effect of milk base and starter culture on acidification, texture, growth, and stability of probiotic bacteria in fermented milk processing, was studied. Two strains of probiotic bacteria were used, Lactobacillus acidophilus LA5 and L. rhamnosus LR35, with two starter cultures. One starter culture consisted only of Streptococcus thermophilus ST7 (single starter culture); the other was a yogurt mixed culture with S. thermophilus ST7 and L. bulgaricus LB12 (mixed starter culture). For the milk base preparation, four commercial dairy ingredients were tested (two milk protein concentrates and two casein hydrolysates). The resulting fermented milks were compared to those obtained with control milk (without enrichment) and milk added with skim milk powder. The performance of the two probiotic strains were opposite. L. acidophilus LA5 grew well on milk but showed a poor stability during storage. L. rhamnosus LR35 grew weakly on milk but was remarkably stable during storage. With the strains tested in this study, the use of the single starter culture and the addition of casein hydrolysate gave the best probiotic cell counts. The fermentation time was of about 11 h, and the probiotic level after five weeks of storage was greater than 106 cfu/ml for L. acidophilus LA5 and 10(7) cfu/ml for L. rhamnosus LR35. However, an optimization of the level of casein hydrolysate added to milk base has to be done, in order to improve texture and flavor when using this dairy ingredient.

Animals↗

Pathogenicity of enterohemorrhagic Escherichia coli in neonatal calves and evaluation of fecal shedding by treatment with probiotic Escherichia coli.

The pathogenicity and fecal shedding of enterohemorrhagic Escherichia coli (EHEC) O26:H11, O111:NM, and O157:H7 were compared in calves (< 1 week of age) with or without prior treatment with probiotic bacteria (competitive exclusion E. coli). Three groups of 12 to 14 calves were used for these treatments. Half of the calves in each group were perorally administered 10(10) CFU of probiotic bacteria per calf, and, 2 days thereafter, 10(8) CFU of a five-strain mixture with one of the three EHEC serotypes per calf were administered to each calf. None of the EHEC serotypes caused clinical disease,and neither gross nor microscopic lesions attributable to EHEC were detected in control or probiotic-treated calves at necropsy. In calves administered E. coli O157:H7, fecal shedding was greatly reduced (> 6 log10 CFU/g) by 8 days after administration, and there was no significant difference (P > 0.05) in fecal shedding of E. coli O157:H7 between probiotic-treated and untreated control groups at that time. In contrast, control calves perorally administered E. coil of serotypes O111:NM or O26:H11 continued to shed substantial populations (10(2.1) to 10(6) CFU/g of feces and 10(2.5) to 10(4.9) CFU/g of feces, respectively) throughout 7 days postadministration of EHEC. In both groups administered either E. coli O111:NM or O26:H11, significantly less (P < 0.05) EHEC was isolated from feces at 7 days postadministration of EHEC and at necropsy from theprobiotic-treated group than from the untreated control group. Overall, neonatal calves shed in the feces from 1 to 7 days following peroral administration of EHEC greater populations of E. coli O111:NM and O26:H111 than E. coli O157:H7. In addition, treatment of calves with probiotic E. coli reduced fecal shedding of E. coli O111:NM and O26:H11 in most calves.

Animals↗

Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials.

The enteric flora comprise approximately 95% of the total number of cells in the human body and are capable of eliciting immune responses while also protecting against microbial pathogens. However, the resident bacterial flora of the gastrointestinal tract (GIT) may also be implicated in the pathogenesis of several chronic conditions such as inflammatory bowel disease (IBD). The University College Cork-based Probiotic Research Group has successfully isolated and identified lactic acid bacteria (LAB) which exhibit beneficial probiotic traits. These characteristics include the demonstration of bile tolerance; acid resistance; adherence to host epithelial tissue; and in vitro antagonism of potentially-pathogenic micro-organisms or those which have been implicated in promoting inflammation. The primary objective of this report is to describe the strategy adopted for the selection of potentially effective probiotic bacteria. The study further describes the evaluation of two members of the resulting panel of micro-organisms (Lactobacillus salivarius subsp. salivarius UCC118 and Bifidobacterium longum infantis 35624) under in vitro conditions and throughout in vivo murine and human feeding trials. Specifically, an initial feeding study completed in Balb/c mice focused upon (i) effective delivery of the probiotic micro-organisms to the GIT and evaluation of the ability of the introduced strains to survive transit through, and possibly colonise, the murine GIT; (ii) accepting the complexity of the hostile GIT and faecal environments, development of a method of enumerating the introduced bacterial strains using conventional microbiological techniques; and (iii) assessment of the effects of administered bacterial strains on the numbers of specific recoverable indigenous bacteria in the murine GIT and faeces. Additional research, exploiting the availability of murine models of inflammatory bowel disease, demonstrated the beneficial effects of administering probiotic combinations of Lactobacillus salivarius UCC118 and Bifidobacterium longum infantis 35624 in prevention of illness-related weight loss. A further ethically-approved feeding trial, successfully conducted in 80 healthy volunteers, demonstrated that yoghurt can be used as a vehicle for delivery of Lactobacillus salivarius strain UCC118 to the human GIT with considerable efficacy in influencing gut flora and colonisation.

Animals↗

Bringing a probiotic-containing functional food to the market: microbiological, product, regulatory and labeling issues.

Properly formulated probiotic-containing foods offer consumers a low risk, low cost dietary component that has the potential to promote health in a variety of ways. Several such products are available commercially, although markets in Japan and Europe are more developed than in the USA. Once healthful attributes of a probiotic product have been identified, there remain microbiological, product, regulatory and labeling issues to be addressed prior to marketing. Microbiological and product issues include safety, effective scale-up for manufacturing, definition of probiotic activity, probiotic stability in the product over the course of product manufacture, shelf-life and consumption, definition of effective dose and target population(s), and development of quality assurance approaches. Examples of probiotic-containing foods are given. Regulatory and labeling issues are complicated because they differ for each country, but are likewise critical because they provide the means for communication of the product benefits to the consumer. The regulatory climate worldwide appears to be one of caution about overstating the benefits of such products but at the same time not preventing corporate commitment to marketing.

Bifidobacterium↗

Probiotics: an overview of beneficial effects.

Food products fermented by lactic acid bacteria have long been used for their proposed health promoting properties. In recent years, selected probiotic strains have been thoroughly investigated for specific health effects. Properties like relief of lactose intolerance symptoms and shortening of rotavirus diarrhoea are now widely accepted for selected probiotics. Some areas, such as the treatment and prevention of atopy hold great promise. However, many proposed health effects still need additional investigation. In particular the potential benefits for the healthy consumer, the main market for probiotic products, requires more attention. Also, the potential use of probiotics outside the gastrointestinal tract deserves to be explored further. Results from well conducted clinical studies will expand and increase the acceptance of probiotics for the treatment and prevention of selected diseases.

Bacillus↗

Probiotics: time for a dose of realism.

There is already a long research and retail history of probiotics, but progress in the scientific and medical validation of these products has been extremely slow. Even now, adequate information by which the consumer and health professional can judge the efficacy and safety of retailed probiotics is lacking. Probiotic products have not been subjected to large scale trials of efficacy that are used in the pharmaceutical industry. Without these trials and subsequent approval by fastidious regulatory agencies such as the FDA (USA), probiotics continue to languish in the self-care health market. Optimistically, a new generation of probiotics may be developed that have medical validity with respect to the prevention or treatment of atopic and inflammatory bowel diseases. These new products, however, will need to be targeted at the alleviation of specific medical conditions, and the mechanistic basis of their effectiveness will need to be provided.

Digestive System↗

Probiotics and medical nutrition therapy.

Probiotics have been defined by The Food Agricultural Organization/World Health Organization (FAO/WHO) as "live microorganisms which when administered in adequate amounts confer a health benefit to the host." They have been used for centuries in the form of dairy-based fermented products, but the potential use of probiotics as a form of medical nutrition therapy has not received formal recognition. A detailed literature review (from 1950 through February 2004) of English-language articles was undertaken to find articles showing a relationship between probiotic use and medical conditions. Medical conditions that have been reportedly treated or have the potential to be treated with probiotics include diarrhea, gastroenteritis, irritable bowel syndrome, and inflammatory bowel disease (Crohn's disease and ulcerative colitis), cancer, depressed immune function, inadequate lactase digestion, infant allergies, failure-to-thrive, hyperlipidemia, hepatic diseases, Helicobacter pylori infections, genitourinary tract infections, and others. The use of probiotics should be further investigated for possible benefits and side-effects in patients affected by these medical conditions.

Adult↗

[Probiotics: from Metchnikoff to the current preventive and therapeutic possibilities].

About a century ago, Metchnikoff first hypothesised that some intestinal bacteria "produce compounds useful against a premature ageing". Since then, studies progressed over last century, leading to a remarkable improvement of the knowledge about the role of intestinal micro-organisms. Nowadays a number of different micro-organisms satisfying certain requisites are named probiotics and are produced on a large scale. At present, a rational use of probiotics with preventive and therapeutic purposes has been proposed not only for some gastrointestinal pathologies, such as the infective diarrhea (as recommended by the Italian Society of Pediatric, the Italian Society of Gastroenterology and Hepatology, the Italian Society of Pediatric Infectious Disease, and by International Societies), but also for other pathologic conditions, such as the atopic dermatitis and related affections (as suggested by the American Academy of Dermatology Association guide lines). Moreover, the use of probiotics is going to be extended to other pathologies, such as the inflammatory intestinal and respiratory diseases, and even to the prevention of tooth decay, although the actual preventive and therapeutic effects of probiotics onto these pathologies have to be carefully investigated. It is unknown if the genius Leonardo Da Vinci (1452-1519), stating that "man's life is built up by food" imagined how nutrients can influence human health, besides being essential for life, as it is today increasingly evident. Avoiding an excessive optimism and the thought that an efficacious panacea for all troubles has been found, there are sound reasons to believe that probiotics, and prebiotics as well, can influence human health, through the prevention and therapy of many diseases, although further studies are still requested to fully clarify the mechanisms of action of these micro-organisms on each pathology.

Animals↗

Probiotics in surgical wound infections: current status.

BACKGROUND: Probiotics--live microorganisms that confer a health benefit when taken in adequate amounts, usually as food supplements--are receiving renewed attention in the medical community. Some have been found to play a role in disease remediation. However, mainstream medicine and science remain divided about the validity of health claims made about them. METHODS: To clarify the potential value of probiotics, we reviewed the scientific data on their role in preventing and treating surgical infections as well as some of our own studies of the effects of certain strains of lactobacilli on surgical implant infections. PRINCIPAL FINDINGS: There is little rigorous evidence that probiotics may be beneficial in the prevention and treatment of wound infections. However, data from 3 clinical trials and from our laboratory indicate that certain strains of probiotic lactobacilli and their byproducts may help reduce infection rates in surgical patients and may ameliorate staphylococcus-related infections of surgical implants. CONCLUSION: Although there is good clinical evidence that certain probiotics may be beneficial in conditions such as diarrheal and inflammatory bowel diseases, more studies are required to apply these concepts to the prevention and treatment of wound and other surgical infections.

Animals↗

Effect of probiotic containing Saccharomyces boulardii on experimental ochratoxicosis in broilers: hematobiochemical studies.

In the present investigation, the toxicopathological effects of ochratoxin A of 0.5 ppm on hematobiochemical parameters of broilers were studied with efficacy of dietary concentration of probiotic containing yeast culture Saccharomyces boulardii of 10 mg/kg of feed. One hundred twenty day old chicks were randomly divided into four groups, thirty chicks each. Groups A and C chicks were offered normal feed and that added with probiotic Saccharomyces boulardii respectively. The birds in group B were fed ochratoxin A of 0.5 ppm of feed. Where as, the birds of group D, were fed with ochratoxin A of 0.5 ppm along with probiotic Saccharomyces boulardii of 10 mg/kg of diet. Hematological studies carried revealed significant decrease in the haemoglobin and packed cell volume in birds of group B and reduced effect in birds of group D due to probiotic. Biochemical profiles revealed significant improvement in probiotic treated group D when compared with decreased values of Total protein, albumin, globulin and increased levels of serum creatinine and SGPT in birds of groups B.

Alanine Transaminase↗

[Probiotics--an alternative for antibiotics?].

The condition and function of gastrointestinal (GI) tract are essential to our well being. Probiotics are defined as the microbial food supplements, which beneficially affect the host by improving its intestinal microbial balance. Probiotics are the functional food ingredients. They are used therapeutically to improve lactose tolerance and to prevent diarrhoea (especially viral diarrhoea in infants, antibiotic-associated diarrhoea, Clostridium difficile-associated diarrhoea and traveler's diarrhoea). Clinical studies suggest that probiotics might be useful in stimulation of the immune system, prevention of allergic diseases, control of GI tract inflammatory diseases and cancer prevention. Probiotic microbial species act by changing the composition of the gut microbionta. The use of non-digestible oligosaccharides (prebiotics) can fortify intestinal microflora and stimulate their growth. This review encompasses information regarding probiotic strains, prebiotics and commercially products (functional food), which can be useful in improving our health.

Anti-Bacterial Agents↗

[Evaluation of the effect of probiotic cultures added to commercial yogurt over a known population of Listeria monocytogenes and Escherichia coli O157:H7].

The effect of probiotic cultures over Listeria monocytogenes and Escherichia coli O157:H7 during yogurt storage was evaluated. Two different yogurt brands, one with additional probiotic cultures (Lactobacillus casei and L. acidophilus) were inoculated with known populations (106 UFC/g) of either L. monocytogenes or E. coli O157:H7 in three different times and stored for 32 days at 5 degrees C. Every four days the count of lactic bacteria, the added pathogens and pH was evaluated, according to the methodology described in the Bacteriological Analytical Manual. The pH and lactic bacteria population were constant during the testing period. Yogurt with additional probiotic cultures reduced the population of L. monocytogenes in 8 days, the population of E. coli O157:H7 in 16; yogurt with no additional probiotics took 20 days to reduce L. monocytogenes to non-detectable levels and even after 28 days of storage, E. coli O157:H7 was cultured. In this work, the beneficial effects of additional probiotic cultures in yogurt is confirmed again.

Animals↗

[Probiotics for inflammatory bowel disease].

Probiotics are defined as live microorganisms that may beneficially affect the host by improving the balance of the intestinal micro flora. In spontaneous animal models of inflammatory bowel disease (IBD), the influence of the enteric flora on gut inflammatory activity has been demonstrated, as germ free animals do not develop disease. Modification of the activity of the intestinal flora using probiotics has been investigated as a way of controlling IBD. However, there is still considerable work to be done before probiotics can be considered as part of the standard treatment of IBD. Probiotic cocktails should be carefully studied and the individual bacterial constituents evaluated in clinical settings. Several studies are currently underway to assess these issues. Further study of placebo controlled trial testing therapeutic role of probiotic bacteria in human trials is warranted.

Animals↗

[Analysis of the probiotic Bifidobacterium and Lactobacillus community in child intestinal flora].

To investigate the distribution of child intestinal flora and the composition of its key probiotics community, study on intestinal flora of 21 Chinese children (age 2 - 5) was conducted, which included bacteria isolation and counting, 16S rDNA sequencing and homology analysis. For identification of the key probiotics such as Bifidobacterium and Lactobacillus in children feces at the species level, the specific primers Im26/Im3 and L159/L677 for PCR amplification of partial 16S rDNA were used. The results show that the composition of child intestinal flora is was relatively stable and almost same to the intestinal flora of the youth (age 20 - 25). Culture-based approaches show that the key probiotic community in feces at the species level was highly different in composition and numbers from individual to individual. B. longum and B. pseudocatenulatum, which are detected at levels of 10(7) CFU/g (wet) in samples and the detection rates are 90.48% and 85.71% respectively, are believed to be major bifidobacterial species in child intestinal microbiota. In addition, B. adolescentis, B. bifidum, B. infantis and B. thermacidophium have also been found. L. mucosae, L. fermentum, L. salivarius, L. ruminis, L. gasseri and L. plantarum are isolated from the stools. L. mucosae (3.68 log10 CFU/g (wet), detection rate 71.43%) and L. fermentum (3.97 log10 CFU/g (wet), detection rate 52.38%) are two dominant species of Lactobacillus. Study on Chinese child intestinal flora, especially on the compositions and numbers of key probiotics in the feces will be very helpful to the development of effective probiotics in future.

Bifidobacterium↗

[Assessment of probiotics according to the international organizations (FAO/WHO)].

The guidelines of international organizations (FAO/WHO) are presented in the paper for the purpose of estimation of probiotic properties of the strains of microorganisms as well as functional food products in respect of their influence on health. Modern scientific researches served as the basis for minimum requirements necessary for the competence of probiotic status. The chart of the experiment sequence is presented that has to be used for probiotics estimation: bacteria systemizing with the use of phenotype and genetic techniques, description of functional properties of the probiotic and estimation of its safety. The in vitro tests for determination of safety of probiotics are described.

Animals↗

[Effects of probiotic bifiform on efficacy of Helicobacter pylori infection treatment].

AIM: To study effects of the probiotic bifiform on efficacy of Helicobacter pylori (HP) eradication in patients with chronic gastritis and ulcer disease. MATERIAL AND METHODS: A total of 98 patients with verified HP infection were divided into two groups. The study group received a week three-component anti-HP therapy+a probiotic. The control group received the same treatment without the probiotic. All the patients were tested for HP before the treatment and one month after the end of the treatment. Cell composition of duodenal mucosa (DM), tissue proinflammatory cytokines, secretory immunoglobulin A (sIgA) in coprofiltrates, serum IgA, IgM, IgG, phagocytic parameters and copromicrobiology were studied. RESULTS: HP eradication rate in the study group was higher than in the control group (89.1 vs 63.5, respectively, p < 0.05). After the treatment, patients of the study group had lower rates of side effects, impaired intestinal biocenosis, tissue cytokines levels but higher concentration of plasmatic cells in CO and cIgA in coprofiltrates. CONCLUSION: The addition of probiotic bifiform to the standard three-component antihelicobacter scheme of the treatment raises its efficacy and is promising treatment of HP. Mechanisms of a potentiating action of the probiotic are related to enhancement of antibacterial activity of local immune reactions.

Adolescent↗

[Role of probiotics in the prevention of neonatal necrotizing enterocolitis: A case-control study].

OBJECTIVE: To assess the role of probiotics in the prevention of neonatal necrotizing enterocolitis (NEC) and to investigate the risk factors for NEC. METHODS: A total of 2528 hospitalized neonates between January 2002 and May 2005 were assigned into either receiving prophylactic use of probiotics bifoco (Prevention group, n=1182) or without probiotics supplementation (Control group, n = 1346). The incidence of NEC was compared between the two groups. The risk factors for NEC were investigated by conditional logistic regression multifactorial analysis. RESULTS: There were 19 cases of NEC in the Control group (1.41%), but only 6 cases in the Prevention group (0.51%) (P < 0.05). Gestational age (OR = 5.521), hypoxicdouble ended arrowischemic encephalopathy (OR = 3.887), specticemia (OR = 4.854) and critical illness scores (OR = 5.989) were the risk factors for NEC, while the prophylactic use of probiotics was an independent protective factor for NEC (OR = 0.255). CONCLUSIONS: The prophylactic use of probiotics may reduce the incidence of NEC in neonates.

Case-Control Studies↗

[Effect of probiotics from bacilli on macrophage functional activity].

The influence of new probiotics from bacilli i.e. biosporin and subalin on the functional activity of murine peritoneal macrophages was studied. After a single oral administration of the probiotics the maximum activation of the macrophages was observed in 4 hours. The activation level depended on both the dose and the probiotic. The highest value of the stimulation index was recorded with subalin. Analogous regularities were stated with parenteral administration of the probiotics. Some mechanisms of activation of peritoneal macrophages after oral administration of probiotics from live microbial cultures are discussed.

Administration, Oral↗